Watching Axsome Therapeutics Shares, Culper Research Issues Short Report
$AXSM
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $140.00 | Overweight | Wells Fargo |
| 8/6/2024 | $95.00 → $106.00 | Neutral → Buy | BofA Securities |
| 7/22/2024 | $130.00 | Buy | Needham |
| 4/29/2024 | $90.00 → $115.00 | Equal-Weight → Overweight | Morgan Stanley |
| 3/19/2024 | $108.00 | Outperform | Robert W. Baird |
| 2/6/2024 | $111.00 | Buy | UBS |
| 1/25/2024 | $126.00 | Outperform | RBC Capital Mkts |
| 12/13/2023 | $125.00 | Buy | Citigroup |
Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth Second expansion of Auvelity psychiatry sales force planned for 1Q 2025 NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025 Topline results of ADVANCE-2 and ACCORD-2 Phase 3 trials of AXS-05 in Alzheimer's disease agitation on track for 4Q 2024 Topline results of ENCORE Phase 3 trial of AXS-12 in narcolepsy on track for 4Q 2024 Topline results of
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts
Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024 Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024; target enrollment reached Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 2H 2024 SUSTAIN Phase 3 trial of solriamf
Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
10-Q - Axsome Therapeutics, Inc. (0001579428) (Filer)
8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)
144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
3 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
Wells Fargo initiated coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $140.00
BofA Securities upgraded Axsome Therapeutics from Neutral to Buy and set a new price target of $106.00 from $95.00 previously
Needham initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $130.00
Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth Second expansion of Auvelity psychiatry sales force planned for 1Q 2025 NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025 Topline results of ADVANCE-2 and ACCORD-2 Phase 3 trials of AXS-05 in Alzheimer's disease agitation on track for 4Q 2024 Topline results of ENCORE Phase 3 trial of AXS-12 in narcolepsy on track for 4Q 2024 Topline results of
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 - Nov. 10, 2024, in Colorado Springs, Colorado. Details for the presentations are as follows: Major Depressive Disorder Title: AXS-05 (Auvelity®) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)Presentation Date and Time: Friday, Nov. 8, 3:35 –
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts. Details for the presentations are as follows: Major Depressive Disorder Title: AXS-05 (Auvelity®) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)Presentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday
SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)
SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)
SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position
On CNBC's “Mad Money Lightning Round,” Jim Cramer said TORM plc (NASDAQ:TRMD) has a “remarkably high dividend yield. And as long as it has that dividend yield, the stock's going to stay up. But, when things start going bad, and they always do in this business, that yield's going to start going down.” On July 23, Evercore ISI Group analyst Jonathan Chappell maintained TORM with an Outperform rating, while increasing the price target from $45 to $48. Cramer recommended buying Trane Technologies plc (NYSE:TT). “Hard to stop a Trane,” he added. Trane Technologies will report its second-quarter financial results on Wednesday, July 31. Analysts expect the company to report quarterly earni
Needham initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), which focuses on central nervous disorders conditions, including depression, Alzheimer’s disease agitation, migraine, narcolepsy, and fibromyalgia. Needham writes that Axsome Therapeutics’ diversified CNS portfolio will help grow the risk-adjusted topline by 8-10x in five years. The analyst anticipates an upside for Axsome Therapeutics on its two marketed drugs, Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness. Related: Axsome Depression Drug’s Commercial Success, Pipeline Potential Undervalued, Analyst Says. Physicians report a positive experience with Auvelity due to its nove
RBC Capital analyst Leonid Timashev reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and maintains $131 price target.